Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-17
1995-10-24
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514412, 514415, 514443, 514461, 514595, 549 58, A01N 4306
Patent
active
054610729
ABSTRACT:
The present invention is concerned with the use of a compound of formula (I): Ar--Y--Q, wherein Ar is either (i) furyl, thienyl, thienyl 1,1-dioxide, pyrryl, pyridyl, benzofuryl, benzothienyl, benzothienyl 1,1-dioxide, indolyl, naphthyl, quinolyl, or tetrahydronaphthyl, any of which is optionally substituted by one or more substituents independently selected from C.sub.1-4 alkyl (which may itself optionally be substituted by one or more halogen atoms), C.sub.1-4 alkoxy, halo, nitro, amino, carboxy, C.sub.1-4 alkoxy-carbonyl and hydroxy, or (ii) phenyl optionally substituted by one or more substituents independently selected from phenyl (which is itself optionally substituted by one or more substituents independently selected from those optional substituents specified in (i) above) and those specified as optional substituents in (i) above, Y is C.sub.1-10 alkylene or C.sub.2-10 alkenylene; Q is formula (II), where R.sup.1 is hydrogen, C.sub.1-4 alkyl, a group as defined for Ar above, or a group of formula -N(R.sup.4)R.sup.5 wherein R.sup.4 is hydrogen or C.sub.1-4 alkyl and R.sup.5 is hydrogen, C.sub.1-4 alkyl, or phenyl optionally substituted by one or more substituents independently selected from those specified as optional substituents in (i) above; and R.sup.2 is hydrogen, C.sub.1-4 alkyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.5-7 cycloalkylamino, C.sub.5-7 cycloalkyl(C.sub.1-4 alkyl)-amino, anilino, N-C.sub.1-4 alkylanilino, or a group as defined for Ar above; or a physiologically acceptable base salt or physiologically functional derivative thereof; in the manufacture of a medicament for the prophylaxis and treatment of conditions for which inhibition of the oxidative modification of lipids is indicated, for example, atherosclerosis. The medicaments obtained thereby and their preparation and use in the prophylaxis and treatment of the aforementioned conditions are also within the scope of the invention.
REFERENCES:
CA83(1):485a 1975.
CA72(7):30144d 1969.
CA72(13):65214d 1969.
Hill, P.: et al. Proc. Soc. Exp. Biol. Med. 148(1) 41-9 1975.
Burroughs Wellcome Co.
Killos Paul J.
LandOfFree
Use of aryl hydroxyurea compounds for the treatment of atheroscl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of aryl hydroxyurea compounds for the treatment of atheroscl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aryl hydroxyurea compounds for the treatment of atheroscl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1886981